Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9247077 | 0.86 | KDM4E (0.62) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL10423391 | 0.84 | KDM4E (0.61) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL9257131 | 0.82 | KDM4E (0.58) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL10334149 | 0.82 | KDM4E (0.75) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL9876458 | 0.81 | KDM4E (0.57) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL9252263 | 0.79 | KDM4E (0.61) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| Hydrochloric Acid SCHEMBL9252872 | 0.78 | KDM4E (0.60) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL15303789 | 0.78 | KDM4E (0.83) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL25834338 | 0.77 | KDM4E (0.69) | KDM4EMEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL9832407 | 0.77 | KDM4E (0.81) | KDM4EMEN1KMT2ACYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5446146-A | Treatment of liver disorders | NIPPON CHEMIPHAR CO., LTD. (JP) | 1995-08-29 | — | — | US | disclosed |
| EP-0326379-B1 | Therapeutic agent for liver disease and piperazine derivatives | NIPPON CHEMIPHAR CO (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5070089-A | INHIBITION OF LIPID PEROXIDATION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1991-12-03 | — | — | US | disclosed |
| EP-0326379-A2 | Therapeutic agent for liver disease and piperazine derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |